Leveraging sequences missing from the human genome to diagnose cancer
暂无分享,去创建一个
J. Witte | M. Hemberg | N. Ahituv | I. Georgakopoulos-Soares | I. Mouratidis | R. Easterlin | O. Barnea | C. Chan | E. Chen | R. Bradley
[1] E. Larsson,et al. Non-coding driver mutations in human cancer , 2021, Nature Reviews Cancer.
[2] T. Becker,et al. Human TERT promoter mutations as a prognostic biomarker in glioma , 2021, Journal of Cancer Research and Clinical Oncology.
[3] N. Friedman,et al. ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells-of-origin , 2021, Nature Biotechnology.
[4] D. Santoni,et al. The farther the better: Investigating how distance from human self affects the propensity of a peptide to be presented on cell surface by MHC class I molecules, the case of Trypanosoma cruzi , 2020, PloS one.
[5] M. Frith,et al. Significant non-existence of sequences in genomes and proteomes , 2020, bioRxiv.
[6] K. D. Sørensen,et al. Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker Potential , 2020, Cells.
[7] F. Meric-Bernstam,et al. Correlation of pathogenic POLE mutations with clinical benefit to immune checkpoint inhibitor therapy. , 2020 .
[8] M. Speicher,et al. Cell-Free DNA and Apoptosis: How Dead Cells Inform About the Living. , 2020, Trends in molecular medicine.
[9] Hayden C. Metsky,et al. Massively multiplexed nucleic acid detection with Cas13 , 2020, Nature.
[10] D. Ledbetter,et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention , 2020, Science.
[11] D. Santoni,et al. In the search of potential epitopes for Wuhan seafood market pneumonia virus using high order nullomers , 2020, Journal of Immunological Methods.
[12] P. V. van Dam,et al. The art of obtaining a high yield of cell-free DNA from urine , 2020, PloS one.
[13] S. Pal,et al. Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers , 2020, Nature Reviews Urology.
[14] O. Barnea,et al. Absent from DNA and protein: genomic characterization of nullomers and nullpeptides across functional categories and evolution , 2020, Genome Biology.
[15] Nuno A. Fonseca,et al. A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns , 2020, Nature Communications.
[16] Steven J. M. Jones,et al. Pan-cancer analysis of whole genomes , 2020, Nature.
[17] Max J. Kellner,et al. Author Correction: SHERLOCK: nucleic acid detection with CRISPR nucleases , 2020, Nature Protocols.
[18] R. Khokha,et al. A Four-Chemokine Signature Is Associated with a T-cell–Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer , 2020, Clinical Cancer Research.
[19] A. Jemal,et al. Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.
[20] Y. Zimmer,et al. A Comparative Analysis of Individual RAS Mutations in Cancer Biology , 2019, Front. Oncol..
[21] David R. Jones,et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants , 2019, Nature Medicine.
[22] M. Schimek,et al. Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection , 2019, Nature Communications.
[23] R. Xu,et al. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. , 2019, JAMA oncology.
[24] Max J. Kellner,et al. SHERLOCK: nucleic acid detection with CRISPR nucleases , 2019, Nature Protocols.
[25] Xianrang Song,et al. Saliva‐derived cfDNA is applicable for EGFR mutation detection but not for quantitation analysis in non‐small cell lung cancer , 2019, Thoracic cancer.
[26] Hyun-Jin Kang,et al. Small-Molecule-Targeting Hairpin Loop of hTERT Promoter G-Quadruplex Induces Cancer Cell Death. , 2019, Cell chemical biology.
[27] R. Rosenquist,et al. Cell‐free tumour DNA testing for early detection of cancer – a potential future tool , 2019, Journal of internal medicine.
[28] G. Bubley,et al. Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer , 2019, bioRxiv.
[29] Prashanth Rawla,et al. Epidemiology of Prostate Cancer , 2019, World journal of oncology.
[30] S. Holdenrieder,et al. The emerging role of cell-free DNA as a molecular marker for cancer management , 2019, Biomolecular detection and quantification.
[31] Ryan L. Collins,et al. The mutational constraint spectrum quantified from variation in 141,456 humans , 2020, Nature.
[32] N. Hawkes. Cancer survival data emphasise importance of early diagnosis , 2019, British Medical Journal.
[33] H. Lenz,et al. Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives. , 2018, Clinical advances in hematology & oncology : H&O.
[34] Alessandro Sette,et al. The Immune Epitope Database (IEDB): 2018 update , 2018, Nucleic Acids Res..
[35] D. Hanahan,et al. Pan-Cancer Landscape of Aberrant DNA Methylation across Human Tumors. , 2018, Cell reports.
[36] N. Murray. Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management , 2018, Biological Research.
[37] Mai-Britt Worm Ørntoft,et al. Review of Blood‐Based Colorectal Cancer Screening: How Far Are Circulating Cell‐Free DNA Methylation Markers From Clinical Implementation? , 2018, Clinical colorectal cancer.
[38] M. Ladomery,et al. Hypoxia leads to significant changes in alternative splicing and elevated expression of CLK splice factor kinases in PC3 prostate cancer cells , 2018, BMC Cancer.
[39] S. Mortimer,et al. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients , 2017, Clinical Cancer Research.
[40] Daniele Santoni,et al. Nullomers and High Order Nullomers in Genomic Sequences , 2016, PloS one.
[41] I. Yeh. Faculty Opinions recommendation of Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. , 2016 .
[42] David C. Jones,et al. Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.
[43] N. Ahituv,et al. Decoding enhancers using massively parallel reporter assays. , 2015, Genomics.
[44] R. C. Poulos,et al. The search for cis-regulatory driver mutations in cancer genomes , 2015, Oncotarget.
[45] Chibo Hong,et al. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer , 2015, Science.
[46] G. Samimi,et al. Methylation of cell-free circulating DNA in the diagnosis of cancer , 2015, Front. Mol. Biosci..
[47] Emily Kang,et al. Cancer-Associated Protein Kinase C Mutations Reveal Kinase’s Role as Tumor Suppressor , 2015, Cell.
[48] Robert J. Schmitz,et al. Methylated DNA is over-represented in whole-genome bisulfite sequencing data , 2014, Front. Genet..
[49] S. Srikantan,et al. The tumor susceptibility gene TMEM127 is mutated in renal cell carcinomas and modulates endolysosomal function. , 2014, Human molecular genetics.
[50] K. Hemminki,et al. TERT promoter mutations in cancer development. , 2014, Current opinion in genetics & development.
[51] Kenneth K Wang,et al. Genome-wide methylation analysis shows similar patterns in Barrett's esophagus and esophageal adenocarcinoma. , 2013, Carcinogenesis.
[52] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[53] Miguel Melo,et al. Frequency of TERT promoter mutations in human cancers , 2013, Nature Communications.
[54] D. Taub,et al. Differential G protein subunit expression by prostate cancer cells and their interaction with CXCR5 , 2013, Molecular Cancer.
[55] Raymond K. Auerbach,et al. An Integrated Encyclopedia of DNA Elements in the Human Genome , 2012, Nature.
[56] Carla Mattos,et al. A comprehensive survey of Ras mutations in cancer. , 2012, Cancer research.
[57] S. Meakin,et al. Role and expression of FRS2 and FRS3 in prostate cancer , 2011, BMC Cancer.
[58] J. Eshleman,et al. Genome-Wide Analysis of Promoter Methylation Associated with Gene Expression Profile in Pancreatic Adenocarcinoma , 2011, Clinical Cancer Research.
[59] M. Stearns,et al. Evidence for Prostate Cancer-Associated Diagnostic Marker-1 , 2004, Clinical Cancer Research.
[60] Ruth Etzioni,et al. Early detection: The case for early detection , 2003, Nature Reviews Cancer.
[61] M. Barry. Prostate-Specific–Antigen Testing for Early Diagnosis of Prostate Cancer , 2001 .
[62] R. Taichman,et al. Minimal Residual Disease in Prostate Cancer. , 2018, Advances in experimental medicine and biology.
[63] W. Chao,et al. Alteration Of Insulin-Like Growth Factor-1 Expression Following The Middle Cerebral Artery Occlusion in Monkeys And Rats : cDNA Microarray , Immunohistochemistry and in Situ Hybridization Studies , 2006 .